文献速递青光眼眼底病与葡萄膜炎神经眼科

线粒体靶向HDAP2保护DBA/2J小鼠视网膜神经节细胞并提高眼压耐受性

Mitochondrial-Targeted HDAP2 Preserves Retinal Ganglion Cells and Increases Pressure Tolerance in DBA/2J Mice.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

本研究在DBA/2J小鼠中测试线粒体靶向肽HDAP2(3 mg/kg腹腔注射,每两天一次,从4月龄开始持续8个月)对高眼压所致视网膜神经节细胞(RGC)损伤的保护作用。结果显示HDAP2在相似眼压暴露下使RGC数量增加约49%(P=0.0063),并提高严重RGC丢失的阈值29 mmHg、降低严重退化风险4.6倍,视神经轴突也得到良好保护。提示HDAP2可能作为降眼压治疗的补充。

要点

  • HDAP2在相似眼压暴露下使RGC数量较未治疗组增加约49%(P=0.0063)。
  • HDAP2将严重RGC丢失的阈值提高29 mmHg,严重退化风险降低4.6倍。
  • HDAP2保护视神经轴突,且对RGC亚型保护作用相似。

核心结论

  • HDAP2在多种眼压暴露范围内保护RGC和轴突,并提高对眼压的耐受性。
  • HDAP2可能补充降眼压治疗,包括正常眼压性和治疗抵抗性青光眼。

研究设计与样本

  • DBA/2J小鼠从4月龄开始接受HDAP2(3 mg/kg,腹腔注射,每两天一次)治疗8个月。
  • 每月测量眼压以追踪压力暴露,通过视网膜铺片RBPMS染色计数RGC和半薄甲苯胺蓝染色视神经切片评估轴突存活。

主要发现

  • 在相似压力暴露下,HDAP2治疗组视网膜RGC数量较未治疗组多约49%(P=0.0063;F(2, 59)=5.524)。
  • 轻度眼压暴露时HDAP2保留的RGC较未治疗组多58%,高眼压时RGC存活率高180%。
  • Kaplan-Meier分析表明HDAP2将严重RGC丢失的阈值提高29毫米汞柱,并将发生严重RGC退化的风险降低4.6倍。
  • 治疗组视神经轴突形态与对照组难以区分,轴突大小分布在各治疗组间无显著变化。

临床怎么用

  • HDAP2可能作为降眼压治疗的辅助手段,用于正常眼压性青光眼或治疗抵抗性青光眼。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Retinal ganglion cell (RGC) loss in glaucoma occurs in a large fraction of patients even after intraocular pressure (IOP) is reduced. Mitochondrial dysfunction is a key mechanism that links elevated IOP to RGC degeneration. We tested whether HDAP2, a novel high-density aromatic peptide that binds cardiolipin to stabilize mitochondrial membranes, can protect RGCs in the DBA/2J mouse model. METHODS: DBA/2J mice received HDAP2 (3 mg/kg, intraperitoneally, every other day) starting at 4 months of age for 8 months. IOP was measured each month to track pressure exposure. RGC survival was assessed by counting RBPMS-stained cells in retinal wholemounts and optic nerve axons in semithin toluidine blue-stained sections. RESULTS: HDAP2-treated retinas had approximately 49% more RGCs than untreated retinas at similar pressure exposures (P = 0.0063; F(2, 59) = 5.524). At mild IOP exposure, HDAP2 preserved 58% more RGCs compared with untreated retinas, and at high IOPs, RGC survival was 180% greater. Kaplan-Meier analysis indicated that HDAP2 increased the threshold for severe RGC loss by 29 millimeters of mercury (mm Hg) and reduced the chance of developing severe RGC degeneration by a factor of 4.6. Optic nerve axons from treated retinas were also well preserved, with axon morphologies appearing indistinguishable from controls. Axon size distributions did not change significantly among the treatment groups, suggesting that protection by HDAP2 was similar among RGC subtypes. CONCLUSIONS: HDAP2 preserved both RGCs and axons across a range of pressure exposures and increased tolerance to IOP. These results suggest that HDAP2 may complement pressure-lowering therapy, including for normal-tension and treatment-refractory glaucoma.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. MacNeil MA, Mentor W, Birk A, et al. Mitochondrial-Targeted HDAP2 Preserves Retinal Ganglion Cells and Increases Pressure Tolerance in DBA/2J Mice. Invest Ophthalmol Vis Sci. 2025. PMID: 41533939. doi:10.1167/iovs.66.15.66

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。